We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Shutterstock/Katrina Elena
Through The Pain Barrier

Two million people could have better lives because of one Dublin company's breakthrough

Mainstay Medical has taken a step closer to bringing its treatment for chronic back pain to market.

DUBLIN-BASED MAINSTAY MEDICAL has announced positive results from a clinical trial of its implant for treating chronic back pain.

The medical-technology firm, which was founded in 2008 and four years later shifted its base from the US to Ireland, has been testing its product ReActiv8 – a device that stimulates nerves controlling key muscles that stabilise a patient’s lower back.

The company said the results of a clinical trial with the first 47 subjects showed “clinically important, statistically significant and lasting improvements” in pain levels and quality of life for sufferers.

Mainstay Medical’s trial was carried out with long-term sufferers of lower back pain, all of whom had tried physical therapy and 70% of whom were using opioids for the pain.

It said that after 90 days, nearly two-thirds of the patients had shown clinically-important improvements in their back pain and a larger share revealed a notable benefit for their quality of life.


Mainstay Medical CEO Peter Crosby said results from the trial showed improvements “better than any other therapy for this group of people as reported in the literature”.

The company is yet to bring ReActiv8 to the market, but over the past two months it has taken out three US patents on its technology.

mainstay1 Mainstay Medical CEO Peter Crosby, front

The current trial will be used to apply for a CE mark, required for the device to be sold in Europe, while the US Food and Drug Administration has also given it the go-ahead for a clinical trial.

Mainstay Medical is currently valued at about €70 million on the Irish Stock Exchange’s Enterprise Securities Market for smaller, growing companies. The firm claims over two million people in the US and EU could be candidates for treatment with the product.

READ: Sick of the gym? Maybe try pole dancing, trapeze or laughter yoga >

READ: Fact and fiction is a scenario like The Terminator really the future? >

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.